IPO registrations (S-1, F-1) · Registrants

CUMBERLAND PHARMACEUTICALS INC

SEC CIK
1087294 · filings on EDGAR ↗
Registration
Form S-1, first filed 2007-05-01, last 2009-07-29; 1 initial registration, 20 amendments
Outcome
Final prospectus filed 2009-08-12; declared effective 2009-08-10
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
TN
Business address
1600 WEST END AVENUE, SUITE 1300, Nashville,, TN 37203
EIN
62-1765329
Ticker
CPIX (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
CUMBERLAND PHARMACEUTICALS INC on the corporate pages

Filings 23

FiledFormWhat it isName as filedEDGAR
2007-05-01S-1S-1 (registration)CUMBERLAND PHARMACEUTICALS INC0000950144-07-004069 ↗
2007-06-22S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-07-005944 ↗
2007-07-06S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-07-006409 ↗
2007-07-11S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-07-006504 ↗
2007-07-23S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-07-006748 ↗
2007-08-06S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-07-007248 ↗
2007-08-29S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-07-008253 ↗
2007-11-16S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-07-010587 ↗
2008-02-01S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-08-000576 ↗
2008-02-19S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-08-001141 ↗
2008-05-21S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-08-004306 ↗
2008-06-09S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-08-004684 ↗
2008-06-20S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-08-004970 ↗
2008-08-12S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-08-006395 ↗
2008-11-12S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-08-008496 ↗
2009-02-18S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-09-001408 ↗
2009-03-18S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-09-002353 ↗
2009-04-10S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-09-003082 ↗
2009-05-12S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950144-09-004230 ↗
2009-07-17S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950123-09-023228 ↗
2009-07-29S-1/AS-1/A (amendment)CUMBERLAND PHARMACEUTICALS INC0000950123-09-026938 ↗
2009-08-10EFFECTEFFECT (declared effective)CUMBERLAND PHARMACEUTICALS INC9999999995-09-002211 ↗
2009-08-12424B4424B4 (final prospectus)CUMBERLAND PHARMACEUTICALS INC0000950123-09-033693 ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Bernard Gordon RDirector; OfficerSenior Vice President282009–2019
Cearnal Martin EDirector; Director,OfficerSr VP/Chief Commercial Officer262009–2022
Edwards RobertDirector122009–2014
Greer Lawrence WDirector82009–2012
KAZIMI A JDirector,Officer,TenPercentOwnerChairman and CEO702009–2026
Lawrence Thomas RDirector222009–2017
Lowrance David LOfficerVice President and CFO42009–2011
Marstiller Jean WOfficerSr. VP & Corp. Secretary82009–2012
Pavliv LeoOfficerSr. Vice President, Operations; SVP and Chief Development Off.; Vice President, Operations272009–2022
Griggs JonathanDirector162010–2021
Jones JamesDirector562010–2026
JACOBS JOEY ADirector202011–2023
Greene Rick ScottOfficerChief Financial Officer62011–2015
Herman James LOfficerSee Remarks; VP and Chief Compliance Office; VP and Corporate Compliance192013–2026
Bonner MichaelOfficerChief Financial Officer142016–2021
Rock AmyOfficerSee Remarks12016
Young CarolineDirector592016–2026
Krogulski KennethDirector592017–2026
Galante Joseph CDirector332018–2026
Hamm John M.OfficerChief Financial Officer; VP Chief Financial Officer82021–2026
Brown Martin S JRDirector62022–2026
Anthony Todd M.OfficerVice Pres Organizational Dev52023–2026
Bitterman Chris T.OfficerVice Pres Sales & Marketing52023–2026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.